Summit Trail Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Summit Trail Advisors's LLY Position: Q2 2026 in Review
Summit Trail Advisors increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $707K and bringing the position to 29,075 shares worth $34.9M. The position accounts for 0.44% of the portfolio, ranked #33.
Summit Trail Advisors first reported a position in LLY in Q4 2017 and has held it in 19 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Summit Trail Advisors held 29,075 shares of Eli Lilly worth $34.9M as of Q2 2026.
- Summit Trail Advisors bought 692 Eli Lilly shares in Q2 2026, an estimated $707K.
- Eli Lilly made up 0.44% of Summit Trail Advisors's portfolio in Q2 2026, its #33 holding.
- Summit Trail Advisors first reported a position in Eli Lilly in Q4 2017 and has held it in 19 quarters since.
- 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.